New Zealand markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
12.89-0.16 (-1.23%)
At close: 04:00PM EST
12.89 0.00 (0.00%)
After hours: 07:55PM EST
Full screen
Trade prices are not sourced from all markets
Previous close13.05
Open13.09
Bid12.72 x 3200
Ask13.04 x 3200
Day's range12.61 - 13.09
52-week range7.09 - 13.35
Volume12,330,060
Avg. volume10,553,913
Market cap14.57B
Beta (5Y monthly)1.01
PE ratio (TTM)N/A
EPS (TTM)-0.50
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Nov 2017
1y target est14.63
  • Business Wire

    Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

    REYKJAVIK, Iceland & PARSIPPANY, N.J., February 24, 2024--Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease,

  • Business Wire

    Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting

    TEL AVIV, Israel & PARSIPPANY, N.J., February 20, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced positive safety, tolerability, and pharmacokinetic data for its anti-TL1A (TEV-’574) asset, a potentially best-in-class human IgG1 monoclonal antibody that targets the tumor necrosis factor (TNF)-like ligand 1A (TL1A) and is designed to offer both anti-inflammatory and anti-fibrotic effects.1-3

  • Reuters

    UPDATE 2-Teva Pharm to stay as unified drugmaker, sees big interest in API business, says CEO

    Teva Pharmaceutical Industries will remain a single company for generic and branded drugs, and expects to see significant interest in its active pharmaceutical ingredients business that it plans to divest, its head said on Tuesday. There has been speculation that Israel-based Teva - the world's largest generic drug maker - would split into two companies handling both the increasingly competitive generics business and its own branded drugs. However, the company will stay unified, and "from an infrastructure point of view, (the two businesses) complement each other incredibly well," Chief Executive Richard Francis said at a news briefing.